What is the revenue and EPS growth rate for Pulse Biosciences year over year?

What were the key takeaways from Pulse Biosciences's earnings call?

What factors drove the changes in Pulse Biosciences's revenue and profit?

What is Pulse Biosciences's gross profit margin?

What is Pulse Biosciences's latest dividend and current dividend yield?

What guidance did Pulse Biosciences's management provide for the next earnings period?

What is the market's earnings forecast for Pulse Biosciences next quarter?

Did Pulse Biosciences beat or miss consensus estimates last quarter?

- **Revenue Milestone**: Generated $86,000 in Q3, marking first commercial sales for Vybrance system.
- **Clinical Momentum**: Over 200 patients treated across thyroid programs; nPulse surgical clamp IDE trial enrolling first patient.
- **Cardiac Device Expansion**: nPulse 360 Catheter IDE submission progressing; European feasibility study shows promising 1-year follow-up data.
- **Financial Position**: $95.2 million cash balance, with Q3 net loss of $19.4 million driven by R&D and commercialization efforts.
- **Strategic Focus**: Scaling Vybrance adoption in select markets while advancing cardiac device trials.

**【CEO Summary Section】**
- **Revenue Generation**: Achieved initial revenue of $86,000 in Q3 2025, driven by Vybrance disposable sales and nPulse capital system placements.
- **Thyroid Ablation Progress**: Over 200 patients treated across pilot programs and PRECISE-BTN study, with physicians reporting high satisfaction and procedural ease. Enrollment in PRECISE-BTN study is 40% complete, targeting 50 patients.
- **Cardiac Device Developments**: 
  - FDA IDE approval for nPulse surgical clamp (NANOCLIP AF) with first patient enrolled; feasibility study in Europe shows ablation times as low as 50 seconds.
  - nPulse 360 Catheter IDE submission progressing; anticipate Q1 2026 trial start. European feasibility study enrolling 150 patients with 1-year follow-up data expected in Q1.
- **Strategic Focus**: Limited market release for Vybrance in select geographies, prioritizing procedure volume and outcome consistency before scaling commercial teams.

**【CFO Financial Commentary】**
- **Financial Performance**: GAAP net loss of $19.4 million (vs. $12.7 million YoY), driven by R&D and commercial expansion. Non-GAAP net loss $13.5 million (vs. $9.4 million YoY). Cash balance $95.2 million, down $11.1 million from Q2 due to operating expenses.
- **Expense Management**: Q3 cash use $13 million, aligned with clinical trial and commercialization investments. Anticipate increased cash use in Q4 with IDE trial enrollment.

**【Q&A Highlights】**
- **nPulse 360 Catheter Trial Funding**: Company plans to self-fund pivotal trial, though open to partnerships for commercialization support.
- **PRECISE-BTN Study Design**: Focuses on composite endpoints including quality of life, symptom reduction, and nodule volume decrease, rather than sole reliance on size reduction.
- **Surgical Clamp Lesion Set**: Surgeon discretion in lesion set based on AF severity; no LAA closure included in trial protocol.


PLSE

PLSE fundamentals

You can ask Aime